Related references
Note: Only part of the references are listed.Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur et al.
LANCET ONCOLOGY (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Katherine L. Nathanson et al.
CLINICAL CANCER RESEARCH (2013)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Oncogenic B-RAFV600E Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion
Suzanah C. Boyd et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Min Yu et al.
SCIENCE (2013)
Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Maria R. Girotti et al.
CANCER DISCOVERY (2013)
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Taru Muranen et al.
CANCER CELL (2012)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells
David J. Mulholland et al.
CANCER RESEARCH (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
KEGG for integration and interpretation of large-scale molecular data sets
Minoru Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2012)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
F. Xing et al.
ONCOGENE (2012)
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Inna V. Fedorenko et al.
BIOCHEMICAL PHARMACOLOGY (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Monitoring a Nuclear Factor-κB Signature of Drug Resistance in Multiple Myeloma
Yun Xiang et al.
MOLECULAR & CELLULAR PROTEOMICS (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy
Qian Huang et al.
NATURE MEDICINE (2011)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer
Elizabeth R. Remily-Wood et al.
PROTEOMICS CLINICAL APPLICATIONS (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
Y. N. Vashisht Gopal et al.
CANCER RESEARCH (2010)
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
Jonas N. Sondergaard et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Jiannong Li et al.
NATURE CHEMICAL BIOLOGY (2010)
The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells
Li-Bing Song et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Functional Proteomics Identifies Targets of Phosphorylation by B-Raf Signaling in Melanoma
William M. Old et al.
MOLECULAR CELL (2009)
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads et al.
NATURE REVIEWS CANCER (2009)
An essential role for fibronectin extra type III domain A in pulmonary fibrosis
Andres F. Muro et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Efficient tumour formation by single human melanoma cells
Elsa Quintana et al.
NATURE (2008)
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
Juergen Cox et al.
NATURE BIOTECHNOLOGY (2008)
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition
Haihe Wang et al.
CANCER RESEARCH (2007)
B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis
K. Boisvert-Adamo et al.
ONCOGENE (2006)
Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10)
ES White et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells
J Rush et al.
NATURE BIOTECHNOLOGY (2005)
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol
AM Domina et al.
ONCOGENE (2004)
Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells
CA Sherman-Baust et al.
CANCER CELL (2003)
Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development
G Li et al.
ONCOGENE (2001)
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors
MY Hsu et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
